Tae Oh Kim

Tae Oh Kim

Auto-generated profile, based on publicly available information

Tae Oh Kim

Department of Gastroenterology, Inje University Haeundae Paik Hospital, Busan, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Korean Medical Science
Verified
Journal Article
Open access
SKSang Yoon Kim
Sang Yoon Kim
HJHye-Kyung Jung
Hye-Kyung Jung
JLJiyoung Lim
Jiyoung Lim
TKTae Oh Kim
Tae Oh Kim
ACA Reum Choe
A Reum Choe
SJSung-Ae Jung
Sung-Ae Jung
Kim SY, et al. J Korean Med Sci. 2019 May;34(21):e158. https://doi.org/10.3346/jkms.2019.34.e158

23 July 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
SSSeung Yong Shin
Seung Yong Shin
SPSoo Jung Park
Soo Jung Park
JIJong Pil Im
Jong Pil Im
HKHyo Jong Kim
Hyo Jong Kim
KLKang-Moon Lee
Kang-Moon Lee
ODon behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Background/Aims: This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC).Methods: A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score.Results: A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients.Conclusions: ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response.

10 September 2019 in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Verified
Journal Article
Open access
PDF file
ACA Reum Choe
A Reum Choe
KSKi-Nam Shim
Ki-Nam Shim
TKTae Oh Kim
Tae Oh Kim
SKSang Yoon Kim
Sang Yoon Kim
JLJiyoung Lim
Jiyoung Lim
SJSung-Ae Jung
Sung-Ae Jung

10 December 2019 in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Verified
Journal Article
Open access
PDF file
TKTae Oh Kim
Tae Oh Kim
KSKi-Nam Shim
Ki-Nam Shim
SKSang Yoon Kim
Sang Yoon Kim
JLJi Young Lim
Ji Young Lim
ACA Reum Choe
A Reum Choe
SJSung-Ae Jung
Sung-Ae Jung